May 30

Pharmaphorum Podcast: Move over CAR-T – the Potential of NK Cells in Cell Therapy

[excerpt] The early successors in cell therapy have mostly been CAR-T therapies, with the T standing for T cells. But T cells aren’t the only option for cell therapy. Promising work is being done with natural killer, or NK cells, a different kind of immune system cell that could work even better in some ways.

On this pharmaphorum podcast, Dr. Fred Aslan, Artiva’s CEO talks with host Jonah Comstock about the potential of NK cells as an allogeneic cell therapy approach in autoimmune disease and the importance of a robust manufacturing process.

Find episode 126 (dated May 30, 2024) on iTunes, Spotify, and Stitcher or on pharmaphorum’s website, which has a podcast player or the option to download the episode.

Recent Posts

See All

PharmaShots: Enhancing Care with NK Cell Therapy

Fred Aslan from Artiva Biotherapeutics in Conversation with PharmaShots discusses: Immune reset in oncology has been observed with approved autologous CAR-T products. A study published in Nature demonstrated B-cell reconstitution and immune reset in systemic lupus erythematosus (SLE) patients treated with a CD19 autologous CAR-T, showcasing promising potential in autoimmune diseases Artiva’s AlloNK, an allogeneic,...

BioProcess Insider: Artiva Discusses Scalable NK Cells to Treat Autoimmune Diseases

Chris Horan, Artiva’s Chief Technical Operations Officer, talks with BioProcess Insider about why decreased risk and inexpensive manufacturing might give allogeneic natural killer (NK) cell therapies the edge over chimeric antigen receptors (CAR)-T therapies. Read the article here.

BiotechTV: Checking in with Artiva CEO Fred Aslan after the Company’s $167 Million IPO

Fred Aslan describes what the funds will enable Artiva to do in the clinic, and why he believes the company’s non-modified NK cell approach is the best platform for using a cell therapy for autoimmune conditions. Watch the interview here.